Resources Management Corp Cassava Sciences Inc Transaction History

Resources Management Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.64 - $30.11 $973 - $2,318	77 Added 334.78%	100 $2,000
Q4 2023 Feb 14, 2024	SELL	$12.64 - $30.11 $973 - $2,318	-77 Reduced 77.0%	23 $2,000
Q2 2023 Aug 16, 2023	SELL	$21.59 - $27.88 $841,729 - $1.09 Million	-38,987 Reduced 99.74%	100 $2,000
Q1 2023 May 11, 2023	BUY	$23.46 - $36.44 $914,635 - $1.42 Million	38,987 Added 38987.0%	39,087 $3.91 Million
Q3 2021 Nov 12, 2021	BUY	$41.79 - $135.3 $4,179 - $13,530	100 New	100 $6,000

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $94.2M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Resources Management Corp , based on Form 13F filings with the SEC.

Stay updated on Resources Management Corp with notifications on news.